(-)-Epigallocatechin-3-gallate suppresses liver metastasis of human colorectal cancer

  • Authors:
    • Takehito Maruyama
    • Soichiro Murata
    • Ken Nakayama
    • Naoki Sano
    • Koichi Ogawa
    • Takeshi Nowatari
    • Takafumi Tamura
    • Reiji Nozaki
    • Kiyoshi Fukunaga
    • Nobuhiro Ohkohchi
  • View Affiliations

  • Published online on: December 13, 2013     https://doi.org/10.3892/or.2013.2925
  • Pages: 625-633
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

(-)-Epigallocatechin-3-gallate (EGCG), the major constituent of green tea, has been shown to inhibit cell proliferation and induce apoptosis in several types of human tumors. The most common site of distant metastases in colorectal cancer is the liver. However, no previous studies have reported the ability of EGCG to suppress liver metastases of human colorectal cancer. The aim of the present study was to elucidate the potential use of EGCG as chemotherapy targeting liver metastases of human colorectal cancer. To assess the effect of EGCG on human colorectal cancer cell lines, RKO and HCT116, cell viability, cell proliferation and apoptosis were measured by cell counting kit-8, BrdU assay and TUNEL staining, respectively. Protein and gene expression were measured by western blot analysis and RT-PCR analysis, respectively. EGCG inhibited cell proliferation and induced apoptosis. EGCG dephosphorylated constitutively activated Akt and increased the activation of p38. EGCG also decreased the expression of vascular endothelial growth factor receptor 2. Additionally, the ability of EGCG to prevent the development of liver metastases of RKO tumors was evaluated in SCID mice. EGCG suppressed angiogenesis and induced apoptosis in liver metastases without associated body weight loss or hepatotoxicity. Furthermore, the liver metastatic area was significantly reduced by EGCG administration. Our findings indicate that EGCG may be useful in the treatment of liver metastases of human colorectal cancer.
View Figures
View References

Related Articles

Journal Cover

2014-February
Volume 31 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Maruyama T, Murata S, Nakayama K, Sano N, Ogawa K, Nowatari T, Tamura T, Nozaki R, Fukunaga K, Ohkohchi N, Ohkohchi N, et al: (-)-Epigallocatechin-3-gallate suppresses liver metastasis of human colorectal cancer. Oncol Rep 31: 625-633, 2014
APA
Maruyama, T., Murata, S., Nakayama, K., Sano, N., Ogawa, K., Nowatari, T. ... Ohkohchi, N. (2014). (-)-Epigallocatechin-3-gallate suppresses liver metastasis of human colorectal cancer. Oncology Reports, 31, 625-633. https://doi.org/10.3892/or.2013.2925
MLA
Maruyama, T., Murata, S., Nakayama, K., Sano, N., Ogawa, K., Nowatari, T., Tamura, T., Nozaki, R., Fukunaga, K., Ohkohchi, N."(-)-Epigallocatechin-3-gallate suppresses liver metastasis of human colorectal cancer". Oncology Reports 31.2 (2014): 625-633.
Chicago
Maruyama, T., Murata, S., Nakayama, K., Sano, N., Ogawa, K., Nowatari, T., Tamura, T., Nozaki, R., Fukunaga, K., Ohkohchi, N."(-)-Epigallocatechin-3-gallate suppresses liver metastasis of human colorectal cancer". Oncology Reports 31, no. 2 (2014): 625-633. https://doi.org/10.3892/or.2013.2925